Sort   by:  
 Page size 
TranscriptomicsGene expression changes during resistance toward vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) therapy in renal cell carcinoma (RCC)
This study was performed to understand the gene expression changes that accompany treatment of renal cell carcinoma (RCC) with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) therapy. Human RCC cell lines were implanted into the flanks of nude beige mice, allowed...
ORGANISM(S): Homo sapiens 
2015-05-21 | E-GEOD-64052 | biostudies-arrayexpress
ProteomicsA network-based approach reveals a novel mechanism of resistance to TKI-therapy in AML
Internal tandem duplications (ITDs) in the FLT3 gene are frequently identified and confer a poor prognosis in patient affected by acute myeloid leukemia (AML). The insertion site of the ITDs in FLT3 significantly impacts the sensitivity to tyrosine kinase inhibitors (TKIs) therapy, affecting patient...
ORGANISM(S): Mus musculus (Mouse) 
2023-03-10 | PXD033953 | Pride
Tyrosine kinase inhibitors Ba/f3 cells Acute myeloid leukemia Midostaurin Flt3 Mouse Phosphoproteomics Tki Quizartinib Aml 
GenomicsTFF3 drives Hippo dependent EGFR-TKI resistance in lung adenocarcinoma
TFF3 drives Hippo dependent EGFR-TKI resistance in lung adenocarcinoma
PRJNA1160153 | ENA
ProteomicsTKI-resistant T790M EGFR Mutation Rewired EGFR Translocation Routes through Switching Interactome in Non-Small Cell Lung Cancer
Epidermal growth factor receptor (EGFR) harboring active mutations, Del19 and L858R, are most common oncogenic mutations in in non-small cell lung cancer (NSCLC) patients. The preferred treatment at first line is tyrosine kinase inhibitor (TKI) administration while the TKI-resistance usually develop...
ORGANISM(S): Homo Sapiens (human) 
2023-05-31 | PXD034228 | JPOST Repository
ProteomicsResearch on the mechanism by which cancer-associated fibroblasts (CAFs) promote EGFR-TKI resistance in non-small cell lung cancer (NSCLC) via secretory proteins
Resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) remains a major clinical challenge in the targeted therapy of non-small cell lung cancer (NSCLC), yet its underlying mechanisms are poorly understood. The tumor microenvironment (TME), which provides a supportive n...
ORGANISM(S): Homo Sapiens 
2025-05-26 | PXD064318 |
GenomicsA Single-cell Atlas of Progressive TKI Resistance in Chronic Myeloid Leukemia
High-dimensional scRNA seq and CyTOF were used to identify features predictive of treatment outcome at diagnosis. An optimal TKI response was characterised by erythroid lineage skewing of the CD34+ HSPC compartment. While TKI-resistant CP was reminiscent of a BC-like state, where HSPCs were enriche...
EGAS00001005509 | EGA
GenomicsAn East-Asian polymorphism underlies BCR-ABL mutation-independent resistance to tyrosine kinase inhibitors in chronic myelogenous leukemia
We used massively parallel DNA sequencing of paired-end ditags (DNA-PET) to identify structural genetic factors associated with disease progression and drug-resistance in representative samples from four CML patients and one CML cell line. The functional consequences of our genetic findings were ev...
ORGANISM(S): Homo sapiens 
2012-02-27 | E-GEOD-28303 | biostudies-arrayexpress
TranscriptomicsEWS TC-71 cell lines: IGF-1R resistant
Ewing's Sarcoma cell lines were made resistant to different IGF-1R drugs to investigate mechanisms and pathways modulated by the resistance. EWS TC-71 cell line was exposed to increasing concentration to three different anti-IGF-1R drugs (HAb AVE1642, TKI NVP-AEW541, HAb CP-751,871, cell lines name...
ORGANISM(S): Homo sapiens 
2012-10-03 | E-GEOD-34027 | biostudies-arrayexpress
TranscriptomicsTFF3 drives Hippo dependent EGFR-TKI resistance in lung adenocarcinoma
Intrinsic and acquired resistance represent major obstacles to optimize outcomes in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) targeted therapy in lung adenocarcinoma (LUAD). Hence, a deeper understanding of EGFR-TKI resistance mechanisms in LUAD will potentially assist ...
ORGANISM(S): Homo sapiens 
2025-10-31 | GSE276990 | GEO
TranscriptomicsCharacterising the cellular activity of new Fibroblast Growth Factor Receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.
Fibroblast growth factor receptors (FGFRs) can act as driving oncoproteins in certain cancers due to mutation, over-expression or activating gene fusions and are therefore attractive drug targets. Here we have characterized tumour cell responses to three new inhibitors of FGFR1-3, AZ12576089, AZ129...
ORGANISM(S): Homo sapiens 
2012-10-02 | E-TABM-1222 | biostudies-arrayexpress
Sort   by:  
 Page size